Pathobiology of Metabolic-Associated Fatty Liver Disease

• Sherouk Fouda ^[1] ; Mohammed Sadiq Jeeyavudeen ^[2] ; Joseph M Pappachan ^[3] ; Venkataraman Jayanthi ^[4]
  1. [1] Royal Melbourne Institute of Technology University

     Royal Melbourne Institute of Technology University

     Australia

     
  2. [2] Edinburgh Centre for Endocrinology & Diabetes, Royal Infirmary of Edinburgh, Edinburgh EH16 4 SA, UK.
  3. [3] Department of Endocrinology & Metabolism, Lancashire Teaching Hospitals NHS Trust, Royal Preston Hospital, Preston PR2 9HT, UK; Manchester Metropolitan University, M15 6BH, UK.
  4. [4] Department of Hepatology, Sriramachandra Institute of Higher Education & Research, Chennai 600116, India.

  Mostrar afiliaciones +
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 52, Nº. 3, 2023, págs. 405-416
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Metabolic-associated fatty liver disease (MAFLD), formerly known as nonalcoholic fatty liver disease, is highly associated with the metabolic syndrome. Given its high heterogeneity in patients along with unpredictable clinical outcomes, MAFLD is difficult to diagnose and manage. MAFLD is associated with obesity, diabetes, metabolic derangements, lipid disorders, cardiovascular disorders, sleep apnea, sarcopenia, gut dysbiosis, and sex hormone-related disorders. Identification of risk factors is imperative in understanding disease heterogeneity and clinical presentation to reliably diagnose and manage patients. The complexity of MAFLD pathobiology is discussed in this review in relation to its association with common metabolic and nonmetabolic disorders.